罗氟司特不被期望用于COPD其它症状，包括肺气肿的治疗。
Roflumilast is not intended to treat another form of COPD which involves primary emphysema.
罗氟司特的安全性和有效性在两项包括1500名40岁及以上患者接受罗氟司特治疗的三期临床试验中得到了证实。
The safety and effectiveness of roflumilast was demonstrated in two Phase 3 clinical studies that included more than 1,500 patients ages 40 and older who received roflumilast.
罗氟司特的安全性和有效性在两项包括1500名40岁及以上患者接受罗氟司特治疗的三期临床试验中得到了证实。
The safety and effectiveness of roflumilast was demonstrated in two Phase 3 clinical studies that included more than 1,500 patients ages 40 and older who received roflumilast.
应用推荐